Three-doses of BNT162b2 COVID-19 mRNA vaccine establishes long-lasting CD8+ T cell immunity in CLL and MDS patients
S. P. A. Hernandez, D. S. Hersby, K. K. Munk, T. Tamhane, D. Trubach, M. Tagliamonte, L. Buonaguro, A. O. Gang, S. R. Hadrup, S. K. Saini
This study evaluates the BNT162b2 vaccine's ability to induce and maintain CD8+ T cell immunity in CLL and MDS patients, showing increased T cell frequencies after booster doses.
bioRxiv · May 13, 2022 · PreprintImmunology